The status of the oral drugs for chronic central serous chorioretinopathy

VernacularTitle:慢性中心性浆液性脉络膜视网膜病变口服药物治疗研究现状
Author: Xiaoshuang JIANG ¹ ; Wei LI ; Yanan LI ; Junjun ZHANG
Author Information

1. 610041成都,四川大学华西医院眼科
Keywords: Central serous chorioretinopathy/drug therapy; Receptors,mineralocorticoid/antagonists & inhibitors; Receptors,glucocorticoid/antagonists & inhibitors; Review
From: Chinese Journal of Ocular Fundus Diseases 2017;33(6):665-668
CountryChina
Language:Chinese
Abstract: Chronic central serous chorioretinopathy (CSC) usually demonstrates frequent recurrence,diffuse leakage and persistent subretinal fluid,which cannot be absorbed,thus lead to photoreceptor damage and poor visual acuity.As glucocorticoids have been implicated in the pathogenesis of chronic CSC,various anti-glucocorticoids oral drugs were used in the clinic to promote retinal fluid absorption and reduce the central retinal thickness of the macula and improve the vision outcomes.In addition,the 5α-reductase-specific inhibitor finasteride,the P450-3A4 inducer rifampicin,circadian rhythmic regulator melatonin,and systemic anti-inflammatory drug methotrexate have also been put into clinical trials for chronic CSC,and achieved certain effects.However,most of the clinical studies on these oral drugs were case reports,but not multi-center randomized clinical trials.The long-term effects of these oral drugs need to be observed and studied further.